ArticleJournal of biological engineering2025
Development of an ethanol-based microbial platform for 3-hydroxypropionic acid production using engineered Pseudomonas putida KT2440.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEthanol is an attractive C2 feedstock for microbial biomanufacturing because it is directly oxidized to acetyl-CoA with favorable redox balance. 3-Hydroxypropionic acid (3-HP), a versatile platform chemical, can be synthesized via the malonyl-CoA and β-alanine pathways. An inducer-free ethanol-to-3-HP process in Pseudomonas putida KT2440 was developed by enabling constitutive expression of both pathways and deleting native 3-HP catabolism and polyhydroxyalkanoate (PHA) synthesis to redirect flux toward the target product. Each route and their co-activation were evaluated, and a genome-scale model constrained with transcriptomic data was applied to identify metabolic nodes governing pathway choice and performance.
resultsShake-flask experiments with 1% (v/v) ethanol showed that the malonyl-CoA pathway yielded higher 3-HP titers than the β-alanine route. Co-activation of both pathways in a PHA-deficient strain improved production to 15.9 mM (1.42 g/L; 179 mg/g ethanol) while reducing acetate overflow. In a fed-batch with continuous ethanol feeding, the engineered strain reached 43.7 mM (3.92 g/L; 154 mg/g ethanol) 3-HP. Deletion of endogenous 3-HP catabolism and PHA synthesis redirected carbon flux toward the product, and additional acetyl-CoA supply was achieved by introducing a heterologous acetaldehyde dehydrogenase. Genome-scale modeling constrained with transcriptomic data revealed dominant flux routing through the glyoxylate shunt and limited oxaloacetate regeneration, explaining the advantage of the malonyl-CoA pathway and the acetate accumulation associated with β-alanine operation.
conclusionsAn inducer-free ethanol-to-3-HP platform was established in P. putida KT2440 by co-activating the malonyl-CoA and β-alanine pathways while eliminating competing sinks such as 3-HP catabolism and PHA synthesis. This approach enhanced yield, reduced acetate overflow, and systems-level analysis identified the glyoxylate shunt and oxaloacetate limitation as key control points. Overall, the study demonstrates an efficient and scalable route for 3-HP production from ethanol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.